Get started Log in

BNR — Burning Rock Biotech News Story

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Market Cap
$164.08m
Enterprise Value
$102.06m
Revenue
CNY539.57m

Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer

Burning Rock Biotech

24/09/2025 07:44

Sept 24 (Reuters) - Burning Rock Biotech Ltd BNR.O:

BURNING ROCK'S ONCOGUIDEâ„˘ ONCOSCREENâ„˘ PLUS CDX SYSTEM NOW APPROVED IN JAPAN AS A COMPANION DIAGNOSTIC FOR CAPIVASERTIB IN BREAST CANCER

Source text: ID:nGNX9st97s

Further company coverage: BNR.O

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Burning Rock Biotech

Burning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
10/09/2026 12:29
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
09/06/2026 11:49
China's Burning Rock Biotech Q4 net loss narrows as costs fall
12/03/2026 11:15
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
20/11/2025 08:28
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer
24/09/2025 07:44